Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding molecular biology. Fulcrum Therapeutics� 10-K is packed with gene-expression charts, DUX4 risk factors, and cash-runway tables that easily exceed 200 pages. Finding the latest losmapimod trial update or the cost of developing pociredir isn’t straightforward—and missing those details can skew valuation models.
Stock Titan solves that problem. Our AI engine breaks down every Fulcrum Therapeutics SEC filing—whether it’s a Fulcrum Therapeutics annual report 10-K simplified or a Fulcrum Therapeutics quarterly earnings report 10-Q filing—into concise highlights, then links directly to the full text on EDGAR. Need real-time alerts? We push Fulcrum Therapeutics Form 4 insider transactions real-time to your dashboard, so you know when executives buy or sell ahead of pivotal readouts. You can also skim an 8-K material events explained summary minutes after it posts.
Here’s what you can do on this page:
- Track Fulcrum Therapeutics insider trading Form 4 transactions and spot buying patterns before Phase 3 data drops.
- Compare R&D spend across quarters with an AI-annotated earnings report filing analysis.
- Review the proxy statement executive compensation section to see how milestones drive management bonuses.
- Use "understanding Fulcrum Therapeutics SEC documents with AI" guides to decode complex gene-regulation jargon.
Whether you’re modeling burn rate, watching for orphan-drug status updates, or verifying executive stock transactions Form 4, Stock Titan surfaces the insights buried deep inside each form—so you can act before the market does.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Fulcrum Therapeutics (NASDAQ:FULC) filed a Form 8-K reporting the results of its 26 June 2025 annual stockholder meeting.
- Shareholders elected Katina Dorton, Robert Gould and Kate Haviland as Class III directors for terms ending in 2028.
- The non-binding say-on-pay proposal passed with 46.1 million votes for, 0.11 million against and 8.3 thousand abstentions.
- Investors recommended an annual frequency for future say-on-pay votes (44.9 million votes for one year).
- Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 49.5 million votes for and no broker non-votes.
No other material corporate actions or operational changes were disclosed.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
What is the core focus of Fulcrum Therapeutics?
Which disease areas are targeted by Fulcrum's programs?
How does Fulcrum approach drug discovery?
What are Fulcrum Therapeutics' lead clinical programs?
How does Fulcrum differentiate itself within the biopharmaceutical industry?
What role do strategic partnerships play in Fulcrum's business model?
How does Fulcrum ensure scientific credibility and transparency?
What makes Fulcrum's technological approach unique?
